ESR1 and breast cancer: Although patients with ER+ BC have a relatively favorable prognosis compared to those with other subtypes, 30–40% are still at risk of relapse due to resistance to endocrine regimens or chemotherapy, which may be related to clinical and biological heterogeneity (3, 4).